ClinicalTrials.gg
CompletedNCT04998136Updated Dec 30, 2025Results posted

Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

A Phase 3 interventional study of Semaglutide 2.4 mg and Placebo (semaglutide 2.4 mg) in Obesity, sponsored by Novo Nordisk A/S. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
51st of 143
150 · median 100
Started
2022
with 18 others
Phase 3
42 of 143
10 open now
Registered
31st of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 51st largest by enrollment, is one of 19 that started in 2022, is one of 42 in phase 3, and was the 31st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study. The study compares the weight loss in people who get semaglutide to the weight loss in people who get placebo. Placebo is a "dummy" medicine that looks like the study medicine, but has no effect on the body.

Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm.

Participants will also have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight.

The study will last for about a year (50 weeks). Participants will have 10 clinic visits and 8 phone calls. At 6 of the clinic visits participants will have blood samples taken.

Participants cannot take part if participants have or have had diabetes. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age above or equal to 18 years at the time of signing .
  • at least 25.0 kg/m\^2 at screening.
  • Both parents of Asian descent.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion criteria

Exclusion Criteria:

  • at least 48 mmol/mol (6.5%) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus.
  • A self-reported change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records.
  • Any participant where a substantial weight loss, in the investigator's opinion, might jeopardise the participant's safety.
  • Renal impairment with estimated (eGFR) below 15 mL/min/1.73 m\^2 at screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Semaglutide 2.4 mg

    Drug: Semaglutide 2.4 mg

  • Placebo comparator
    Placebo

    Drug: Placebo (semaglutide 2.4 mg)

Interventions

  • Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg

  • DrugPlacebo (semaglutide 2.4 mg)

    Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks

06

What researchers measure

Primary outcomes

  1. Change in Body Weight (%) : In-trial Observation Period

    Change in percentage (%) of body weight from baseline (week 0) to end of treatment (week 44) is presented in this outcome measure and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial observation period: The time period where the participants were assessed in the study. The in-trial observation period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  2. Change in Body Weight (%) : On-treatment Observation Period

    Change in percentage (%) of body weight from baseline (week 0) to end of treatment (week 44) is presented in this endpoint. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: The time period where participants were treated with trial product. It started from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) including 2 weeks of follow up. It excludes off treatment period which is defined as at least 2 consecutive missed doses.

    Time frame: Baseline (week 0), end of treatment (week 44)

  3. Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : In-trial Observation Period

    Number of participants who achieved body weight reduction more than or equal to 5 percent is presented at week 44 in this outcome measure and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial observation period: The time period where the participants were assessed in the study. The in-trial observation period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: At week 44

  4. Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : On-treatment Observation Period

    Number of participants who achieved body weight reduction more than or equal to 5 percent is presented at week 44 in this endpoint. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: the time period where partici-pants were treated with trial product. It started from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) including 2 weeks of follow up. It excludes off treatment period which is defined as at least 2 consecutive missed doses.

    Time frame: At week 44

Secondary outcomes

  1. Number of Participants Achieved ≥ 10% Body Weight Reduction (Yes/no)

    Number of participants who achieved body weight reduction more than or equal to 10 percent is presented at week 44 and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: At week 44

  2. Number of Participants Achieved ≥15% Body Weight Reduction (Yes/no)

    Number of participants who achieved body weight reduction more than or equal to 15 percent is presented at week 44 and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: At week 44

  3. Number of Participants Achieved ≥20% Body Weight Reduction (Yes/no)

    Number of participants who achieved body weight reduction more than or equal to 20 percent is presented at week 44 and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: At week 44

  4. Change in Waist Circumference

    Change in waist circumference from baseline (week 0) to the end of treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  5. Change in Body Weight (kg)

    Change in body weight in kilogram (kg) is presented from baseline (week 0) to the end of treatment (week 44) and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  6. Change in Body Mass Index

    Change in body mass index from baseline (week 0) to end of treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  7. Change in Systolic Blood Pressure (mmHg)

    Change in systolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  8. Change in Diastolic Blood Pressure

    Change in diastolic blood pressure from baseline (week 0) to end of the treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  9. Change in Total Cholesterol (mg/dL) - Ratio to Baseline

    Change in total cholesterol in milligram per deciliter (mg/dL) from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  10. Change in Total Cholesterol (mmol/L) - Ratio to Baseline

    Change in total cholesterol in millimoles per liter (mmol/L) from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  11. Change in High-density Lipoprotein (HDL) Cholesterol (mg/dL) - Ratio to Baseline

    Change in HDL cholesterol in mg/dL from (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  12. Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in HDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  13. Change in Low-density Lipoprotein (LDL) Cholesterol (mg/dL) - Ratio to Baseline

    Change in LDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  14. Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

    Change in LDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 44) as ratio to baseline presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  15. Change in Triglycerides (mg/dL) - Ratio to Baseline

    Change in triglycerides in mg/dL from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  16. Change in Triglycerides (mmol/L) - Ratio to Baseline

    Change in triglycerides in mmol/L from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  17. Change in High-sensitivity C-reactive Protein (hsCRP) (mg/L) - Ratio to Baseline

    Change in hsCRP in milligram per liter (mg/L) from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  18. Change in HbA1c (%)

    Change in glycosylated haemoglobin (HbA1c) in percentage from baseline (week 0) to end of treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

  19. Change in HbA1c (mmol/Mol)

    Change in glycosylated heamoglobin (HbA1c) in millimoles per mole (mmol/mol) from baseline (week 0) to end of treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

    Time frame: Baseline (week 0), end of treatment (week 44)

07

Results

Posted Apr 3, 2025

Participant flow

The trial was conducted at 13 sites in Republic of Korea and Thailand.

Participant flow — Overall Study
MilestoneSemaglutidePlacebo
Started10149
Full analysis set10149
Safety analysis set10149
Completed10149
Not completed00

Outcome measures

PrimaryChange in Body Weight (%) : In-trial Observation Period

Change in percentage (%) of body weight from baseline (week 0) to end of treatment (week 44) is presented in this outcome measure and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial observation period: The time period where the participants were assessed in the study. The in-trial observation period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Percentage of body weight
Change in Body Weight (%) : In-trial Observation Period
Percentage of body weightSemaglutidePlacebo
Change in Body Weight (%) : In-trial Observation Period-16.4 ± 7.3-2.6 ± 5.8
Statistical analysis
  • Semaglutide vs Placebo · ANCOVA · p = <0.0001 · Treatment difference: -12.99 · 95% CI -15.28 to -10.70
PrimaryChange in Body Weight (%) : On-treatment Observation Period

Change in percentage (%) of body weight from baseline (week 0) to end of treatment (week 44) is presented in this endpoint. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: The time period where participants were treated with trial product. It started from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) including 2 weeks of follow up. It excludes off treatment period which is defined as at least 2 consecutive missed doses.

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Percentage of body weight
Change in Body Weight (%) : On-treatment Observation Period
Percentage of body weightSemaglutidePlacebo
Change in Body Weight (%) : On-treatment Observation Period-16.4 ± 7.4-2.7 ± 5.8
Statistical analysis
  • Semaglutide vs Placebo · MMRM · p = <0.0001 · Treatment difference: -13.40 · 95% CI -15.70 to -11.11
PrimaryNumber of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : In-trial Observation Period

Number of participants who achieved body weight reduction more than or equal to 5 percent is presented at week 44 in this outcome measure and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial observation period: The time period where the participants were assessed in the study. The in-trial observation period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : In-trial Observation Period
ParticipantsSemaglutidePlacebo
Yes9612
No436
Statistical analysis
  • Semaglutide vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 88.87 · 95% CI 21.96 to 359.61
PrimaryNumber of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : On-treatment Observation Period

Number of participants who achieved body weight reduction more than or equal to 5 percent is presented at week 44 in this endpoint. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: the time period where partici-pants were treated with trial product. It started from the date of first trial product administration (week 0) to the date of last trial product administration (week 44) including 2 weeks of follow up. It excludes off treatment period which is defined as at least 2 consecutive missed doses.

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : On-treatment Observation Period
ParticipantsSemaglutidePlacebo
Yes9212
No435
Statistical analysis
  • Semaglutide vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 253.47 · 95% CI 38.41 to 1672.57
SecondaryNumber of Participants Achieved ≥ 10% Body Weight Reduction (Yes/no)

Number of participants who achieved body weight reduction more than or equal to 10 percent is presented at week 44 and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants Achieved ≥ 10% Body Weight Reduction (Yes/no)
ParticipantsSemaglutidePlacebo
Yes785
No2243
SecondaryNumber of Participants Achieved ≥15% Body Weight Reduction (Yes/no)

Number of participants who achieved body weight reduction more than or equal to 15 percent is presented at week 44 and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants Achieved ≥15% Body Weight Reduction (Yes/no)
ParticipantsSemaglutidePlacebo
Yes532
No4746
SecondaryNumber of Participants Achieved ≥20% Body Weight Reduction (Yes/no)

Number of participants who achieved body weight reduction more than or equal to 20 percent is presented at week 44 and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
At week 44
Reported as:
Count of participants · Participants
Number of Participants Achieved ≥20% Body Weight Reduction (Yes/no)
ParticipantsSemaglutidePlacebo
Yes300
No7048
SecondaryChange in Waist Circumference

Change in waist circumference from baseline (week 0) to the end of treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Centimeter (cm)
Change in Waist Circumference
Centimeter (cm)SemaglutidePlacebo
Change in Waist Circumference-12.0 ± 7.5-3.0 ± 5.4
SecondaryChange in Body Weight (kg)

Change in body weight in kilogram (kg) is presented from baseline (week 0) to the end of treatment (week 44) and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Kg
Change in Body Weight (kg)
KgSemaglutidePlacebo
Change in Body Weight (kg)-13.0 ± 5.5-2.0 ± 5.1
SecondaryChange in Body Mass Index

Change in body mass index from baseline (week 0) to end of treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Kilogram per square meter (kg/m^2)
Change in Body Mass Index
Kilogram per square meter (kg/m^2)SemaglutidePlacebo
Change in Body Mass Index-4.9 ± 2.1-0.8 ± 1.9
SecondaryChange in Systolic Blood Pressure (mmHg)

Change in systolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Millimeter of mercury (mmHg)
Change in Systolic Blood Pressure (mmHg)
Millimeter of mercury (mmHg)SemaglutidePlacebo
Change in Systolic Blood Pressure (mmHg)-11 ± 14-1 ± 13
SecondaryChange in Diastolic Blood Pressure

Change in diastolic blood pressure from baseline (week 0) to end of the treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · MmHg
Change in Diastolic Blood Pressure
MmHgSemaglutidePlacebo
Change in Diastolic Blood Pressure-4 ± 110 ± 12
SecondaryChange in Total Cholesterol (mg/dL) - Ratio to Baseline

Change in total cholesterol in milligram per deciliter (mg/dL) from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of total cholesterol
Change in Total Cholesterol (mg/dL) - Ratio to Baseline
Ratio of total cholesterolSemaglutidePlacebo
Change in Total Cholesterol (mg/dL) - Ratio to Baseline0.91 ± 15.71.03 ± 12.3
SecondaryChange in Total Cholesterol (mmol/L) - Ratio to Baseline

Change in total cholesterol in millimoles per liter (mmol/L) from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of total cholesterol
Change in Total Cholesterol (mmol/L) - Ratio to Baseline
Ratio of total cholesterolSemaglutidePlacebo
Change in Total Cholesterol (mmol/L) - Ratio to Baseline0.91 ± 15.71.03 ± 12.3
SecondaryChange in High-density Lipoprotein (HDL) Cholesterol (mg/dL) - Ratio to Baseline

Change in HDL cholesterol in mg/dL from (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of HDL cholesterol
Change in High-density Lipoprotein (HDL) Cholesterol (mg/dL) - Ratio to Baseline
Ratio of HDL cholesterolSemaglutidePlacebo
Change in High-density Lipoprotein (HDL) Cholesterol (mg/dL) - Ratio to Baseline1.00 ± 15.31.04 ± 13.7
SecondaryChange in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in HDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of HDL cholesterol
Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of HDL cholesterolSemaglutidePlacebo
Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline1.00 ± 15.31.04 ± 13.7
SecondaryChange in Low-density Lipoprotein (LDL) Cholesterol (mg/dL) - Ratio to Baseline

Change in LDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of LDL cholesterol
Change in Low-density Lipoprotein (LDL) Cholesterol (mg/dL) - Ratio to Baseline
Ratio of LDL cholesterolSemaglutidePlacebo
Change in Low-density Lipoprotein (LDL) Cholesterol (mg/dL) - Ratio to Baseline0.93 ± 25.61.04 ± 21.6
SecondaryChange in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

Change in LDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 44) as ratio to baseline presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of LDL cholesterol
Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline
Ratio of LDL cholesterolSemaglutidePlacebo
Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline0.93 ± 25.61.04 ± 21.6
SecondaryChange in Triglycerides (mg/dL) - Ratio to Baseline

Change in triglycerides in mg/dL from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of triglycerides
Change in Triglycerides (mg/dL) - Ratio to Baseline
Ratio of triglyceridesSemaglutidePlacebo
Change in Triglycerides (mg/dL) - Ratio to Baseline0.72 ± 40.90.96 ± 42.1
SecondaryChange in Triglycerides (mmol/L) - Ratio to Baseline

Change in triglycerides in mmol/L from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of triglycerides
Change in Triglycerides (mmol/L) - Ratio to Baseline
Ratio of triglyceridesSemaglutidePlacebo
Change in Triglycerides (mmol/L) - Ratio to Baseline0.72 ± 40.90.96 ± 42.1
SecondaryChange in High-sensitivity C-reactive Protein (hsCRP) (mg/L) - Ratio to Baseline

Change in hsCRP in milligram per liter (mg/L) from baseline (week 0) to end of treatment (week 44) as ratio to baseline is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Geometric mean · Ratio of hsCRP
Change in High-sensitivity C-reactive Protein (hsCRP) (mg/L) - Ratio to Baseline
Ratio of hsCRPSemaglutidePlacebo
Change in High-sensitivity C-reactive Protein (hsCRP) (mg/L) - Ratio to Baseline0.54 ± 170.00.89 ± 73.7
SecondaryChange in HbA1c (%)

Change in glycosylated haemoglobin (HbA1c) in percentage from baseline (week 0) to end of treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Percentage of HbA1c
Change in HbA1c (%)
Percentage of HbA1cSemaglutidePlacebo
Change in HbA1c (%)-0.4 ± 0.30.0 ± 0.2
SecondaryChange in HbA1c (mmol/Mol)

Change in glycosylated heamoglobin (HbA1c) in millimoles per mole (mmol/mol) from baseline (week 0) to end of treatment (week 44) is presented and it was evaluated based on the data from in-trial observation period. For end of treatment visit, data collected up to week 49 during the in-trial observation period is included in this Outcome Measure. In-trial period: The time period where the participants were assessed in the study. The in-trial period begins on the date of randomization (week 0) and ends at the end of study visit (week 49).

Time frame:
Baseline (week 0), end of treatment (week 44)
Reported as:
Mean · Mmol/mol
Change in HbA1c (mmol/Mol)
Mmol/molSemaglutidePlacebo
Change in HbA1c (mmol/Mol)-4.5 ± 3.2-0.1 ± 2.3

Adverse events

Collected over From (week 0) to (week 49).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide0/101 (0%)13/101 (12.9%)80/101 (79.2%)
Placebo0/49 (0%)4/49 (8.2%)34/49 (69.4%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventSemaglutidePlacebo
AppendicitisInfections and infestations0/1011/49
Face injuryInjury, poisoning and procedural complications0/1011/49
GastroenteritisInfections and infestations2/1011/49
HaematemesisGastrointestinal disorders0/1011/49
Limb injuryInjury, poisoning and procedural complications0/1011/49
Abdominal painGastrointestinal disorders1/1010/49
Animal biteInjury, poisoning and procedural complications1/1010/49
Chikungunya virus infectionInfections and infestations1/1010/49
CholelithiasisHepatobiliary disorders1/1010/49
Colitis ischaemicGastrointestinal disorders1/1010/49
Most frequent other events
Showing 10 of 14
Most frequent other events
EventSemaglutidePlacebo
NauseaGastrointestinal disorders38/1017/49
COVID-19Infections and infestations15/10116/49
DiarrhoeaGastrointestinal disorders28/1013/49
NasopharyngitisInfections and infestations12/10112/49
ConstipationGastrointestinal disorders22/1018/49
Upper respiratory tract infectionInfections and infestations8/1017/49
Decreased appetiteMetabolism and nutrition disorders13/1012/49
HeadacheNervous system disorders13/1013/49
DyspepsiaGastrointestinal disorders12/1015/49
DizzinessNervous system disorders11/1013/49

Baseline characteristics

Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(Years)SemaglutidePlaceboTotal
Mean41 ± 1037 ± 1139 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)SemaglutidePlaceboTotal
Female7833111
Male231639
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SemaglutidePlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino10149150
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SemaglutidePlaceboTotal
American Indian or Alaska Native000
Asian10149150
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

16 sites
  • Konyang University Hospital
    Daejeon, 35365, South Korea
  • Dongguk University Ilsan Hospital_Gyeonggi-do
    Gyeonggi-do, 10326, South Korea
  • Hallym University Sacred Heart Hospital
    Gyeonggi-do, 14068, South Korea
  • Gachon University Gil Hospital
    Incheon, 405-760, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do, 13620, South Korea
  • SMG-SNU Boramae Medical Center
    Seoul, 07061, South Korea
  • Ajou University Hospital
    Suwon, 16499, South Korea
  • King Chulalongkorn Memorial Hospital_Bangkok
    Bangkok, 10330, Thailand
  • King Chulalongkorn Memorial Hospital_Endocrinology
    Bangkok, 10330, Thailand
  • King Chulalongkorn Memorial Hospital_Obstetrics&Gynecology
    Bangkok, 10330, Thailand
  • Obstetrics&Gynecology King Chulalongkorn Memorial Hospital
    Bangkok, 10330, Thailand
  • Ramathibodi Hospital_Nutrition and Biochemical
    Bangkok, 10400, Thailand
  • Siriraj Hospital_Bangkok_1
    Bangkok, 10700, Thailand
  • Siriraj Hospital_Dept Cardio
    Bangkok, 10700, Thailand
  • Siriraj Institute of Clinical Research
    Bangkok, 10700, Thailand
  • Maharaj Nakorn Chiang Mai_Hematology and Oncology
    Chiang Mai, 50200, Thailand
09

References and documents

Publications

  • Lim S, Buranapin S, Bao X, Quiroga M, Park KH, Kang JH, Rinnov AR, Suwanagool A. Once-weekly semaglutide 2.4 mg in an Asian population with obesity, defined as BMI >/=25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025 Oct;13(10):838-847. doi: 10.1016/S2213-8587(25)00164-0. Epub 2025 Aug 15. PubMed 40825340 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Oct 2023, 14 months.

Results were first posted in Apr 2025, 1 year 5 months after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 14 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Aug 10, 2021
StartActual
Aug 15, 2022
Primary completionActual
Oct 16, 2023
CompletionActual
Nov 20, 2023
Results first posted
Apr 3, 2025
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04998136
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 10, 2021
Start date
Aug 15, 2022
Primary completion
Oct 16, 2023
Completion
Nov 20, 2023
Results posted
Apr 3, 2025
Last update
Dec 30, 2025

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion